Abstract
Purpose of Review
This review gives an overview of the medicinal uses of synthetic cannabinoids and other related aspects on the basis of recent as well as earlier studies that the authors considered relevant to the context and scope of the review.
Recent Findings
Synthetic cannabinoids are laboratory synthesized products eliciting effects way more than their natural counterparts. These compounds are more potent in generating intoxicating effects and are also difficult to be detected in conventional screening tests. Their clinical side effects are also more pronounced than natural cannabinoids, and their antidotes are also not known. However, they are also therapeutically found to be very effective in many health conditions, as these act by interacting with almost ubiquitously distributed cannabinoid receptors (CB1 and CB2) in the human body and by other mechanisms also that do not involve these receptors.
Summary
All the issues related to their appropriate dosage, mode of action, acute and chronic effects in vivo, interaction with other drugs, their metabolism, etc. need much research to be done so that it will be easier to predict their different aspects in human subjects in more appropriate way. Further, development of strict legislation and regulation is required to be done so that their abuse can be curbed, and toxic effects can be reduced, but medicinal benefits and usage can be enhanced.
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs40495-018-0165-y/MediaObjects/40495_2018_165_Fig1_HTML.png)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs40495-018-0165-y/MediaObjects/40495_2018_165_Fig2_HTML.png)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs40495-018-0165-y/MediaObjects/40495_2018_165_Fig3_HTML.png)
Similar content being viewed by others
References
Burstein SH, Zurier RB. Cannabinoids, endocannabinoids, and related analogs in inflammation. AAPS J. 2009;11(1):109–19. https://doi.org/10.1208/s12248-009-9084-5.
Patil KR, Goyal SN, Sharma C, Patil CR, Ojha S. Phytocannabinoids for cancer therapeutics: recent updates and future prospects. Curr Med Chem. 2015;22(30):3472–501. https://doi.org/10.2174/0929867322666150716115057.
Morales P, Hurst DP, Reggio PH. Molecular targets of the phytocannabinoids: a complex picture. Prog Chem Org Nat Prod. 2017;103:103–31. https://doi.org/10.1007/978-3-319-45541-9_4.
Mechoulam R, Gaoni Y. The absolute configuration of delta-1-tetrahydrocannabinol, the major active constituent of hashish. Tetrahedron Lett. 1967;12:1109–11.
Mechoulam R, Peters M, Murillo-Rodrigiiez E, Hanus LO. Cannabidiol—recent advances. Chem Biodivers. 2007;4(8):1678–92. https://doi.org/10.1002/cbdv.200790147.
Schuel H, Burkman LJ, Lippes J, Crickard K, Forester E, Piomelli D, et al. N-Acylethanolamines in human reproductive fluids. Chem Phys Lipids. 2002, 121;(1–2):211–27. https://doi.org/10.1016/S0009-3084(02)00158-5.
Giuffrida A, Piomelli D. The endocannabinoid system: a physiological perspective on its role in psychomotor control. Chem Phys Lipids. 2000;108(1–2):151–8. https://doi.org/10.1016/S0009-3084(00)00193-6.
Murillo-Rodriguez E, Sanchez-Alavez M, Navarro L, Martinez-Gonzalez D, Drucker-Colin R, Prospero-Garcia O. Anandamide modulates sleep and memory in rats. Brain Res. 1998;812(1–2):270–4. https://doi.org/10.1016/S0006-8993(98)00969-X.
Howlett AC, Mukhopadhyay S. Cellular signal transduction by anandamide and 2-arachidonoylglycerol. Chem Phys Lipids. 2000;108(1–2):53–70. https://doi.org/10.1016/S0009-3084(00)00187-0.
Pertwee RG. Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond. Addict Biol. 2008;13(2):147–59. https://doi.org/10.1111/j.1369-1600.2008.00108.x.
Khan MI, Sobocinska AA, Czarnecka AM, Krol M, Botta B, Szczylik C. The therapeutic aspects of the endocannabinoid system (ECS) for cancer and their development: from nature to laboratory. Curr Pharm Design. 2016;22(12):1756–66. https://doi.org/10.2174/1381612822666151211094901.
Mills B, Yepes A, Nugent K. Synthetic cannabinoids. Am J Med Sci. 2015;350(1):59–62. https://doi.org/10.1097/MAJ.0000000000000466.
Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Therapeut. 1997;74(2):129–80. https://doi.org/10.1016/S0163-7258(97)82001-3.
Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990;346(6284):561–4. https://doi.org/10.1038/346561a0.
Munro S, Thomas KL, Abushaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365(6441):61–5. https://doi.org/10.1038/365061a0.
Rom S, Persidsky Y. Cannabinoid receptor 2: potential role in immunomodulation and neuroinflammation. J NeuroImmune Pharmacol. 2013;8(3):608–20. https://doi.org/10.1007/s11481-013-9445-9.
Schicho R, Storr M. Alternative targets within the endocannabinoid system for future treatment of gastrointestinal diseases. Can J Gastroenterol. 2011;25(7):377–83. https://doi.org/10.1155/2011/953975.
De Petrocellis L, Di Marzo V. An introduction to the endocannabinoid system: from the early to the latest concepts. Best Pract Res Cl En. 2009;23(1):1–15. https://doi.org/10.1016/j.beem.2008.10.013.
Anand P, Whiteside G, Fowler CJ, Hohmann AG. Targeting CB2 receptors and the endocannabinoid system for the treatment of pain. Brain Res Rev. 2009;60(1):255–66. https://doi.org/10.1016/j.brainresrev.2008.12.003.
del Pulgar T, Velasco G, Guzman M. The CB1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt. Biochem J. 2000;347:369–73.
Ameri A. The effects of cannabinoids on the brain. Prog Neurobiol. 1999;58(4):315–48.
Tampus R, Yoon SS, de la Pena JB, Botanas CJ, Kim HJ, Seo JW, et al. Assessment of the abuse liability of synthetic cannabinoid agonists JWH-030, JWH-175, and JWH-176. Biomol Ther. 2015;23(6):590–6. https://doi.org/10.4062/biomolther.2015.120.
Huffman JW, Padgett LW. Recent developments in the medicinal chemistry of cannabimimetic indoles, pyrroles and indenes. Curr Med Chem. 2005;12(12):1395–411. https://doi.org/10.2174/0929867054020864.
Theunissen EL, Hutten NRPW, Mason NL, Toennes SW, Kuypers KPC, Perna EBDF, et al. Neurocognition and subjective experience following acute doses of the synthetic cannabinoid JWH-018: a phase 1, placebo-controlled, pilot study. Brit J Pharmacol. 2018;175(1):18–28. https://doi.org/10.1111/bph.14066.
Yun J, Yoon KS, Lee TH, Lee H, Gu SM, Song YJ, et al. Synthetic cannabinoid, JWH-030, induces QT prolongation through hERG channel inhibition. Toxicol Res-Uk. 2016;5(6):1663–71. https://doi.org/10.1039/c6tx00259e.
Griffin G, Atkinson PJ, Showalter VM, Martin BR, Abood ME. Evaluation of cannabinoid receptor agonists and antagonists using the guanosine-5’-O-(3-[35S]thio)-triphosphate binding assay in rat cerebellar membranes. J Pharmacol Exp Ther. 1998;285(2):553–60.
Norooznezhad AH, Norooznezhad F. Cannabinoids: possible agents for treatment of psoriasis via suppression of angiogenesis and inflammation. Med Hypotheses. 2017;99:15–8. https://doi.org/10.1016/j.mehy.2016.12.003.
Sanchez C, de Ceballos ML, Gomez del Pulgar T, Rueda D, Corbacho C, Velasco G, et al. Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. Cancer Res. 2001;61(15):5784–9.
Blazquez C, Salazar M, Carracedo A, Lorente M, Egia A, Gonzalez-Feria L, et al. Cannabinoids inhibit glioma cell invasion by down-regulating matrix metalloproteinase-2 expression. Cancer Res. 2008;68(6):1945–52. https://doi.org/10.1158/0008-5472.Can-07-5176.
Li Q, Guo HC, Maslov LN, Qiao XW, Zhou JJ, Zhang Y. Mitochondrial permeability transition pore plays a role in the cardioprotection of CB2 receptor against ischemia-reperfusion injury. Can J Physiol Pharm. 2014;92(3):205–14. https://doi.org/10.1139/cjpp-2013-0293.
Grim TW, Samano KL, Ignatowska-Jankowska B, Tao Q, Sim-Selly LJ, Selley DE, et al. Pharmacological characterization of repeated administration of the first generation abused synthetic cannabinoid CP47,497. J Basic Clin Physiol Pharmacol. 2016;27(3):217–28. https://doi.org/10.1515/jbcpp-2015-0118.
Gorbunov AS, Maslov LN, Tsibulnikov SY, Khaliulin IG, Tsepokina AV, Khutornaya MV, et al. CB-receptor agonist HU-210 mimics the postconditioning phenomenon of isolated heart. B Exp Biol Med+. 2016;162(1):27–9. https://doi.org/10.1007/s10517-016-3536-6.
Ramirez BG, Blazquez C, del Pulgar TG, Guzman N, de Ceballos MAL. Prevention of Alzheimer’s disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci 2005;25(8):1904–1913. doi:https://doi.org/10.1053/Jneurosci.4540-04.2005.
Kokona D, Georgiou PC, Kounenidakis M, Kiagiadaki F, Thermos K Endogenous synthetic cannabinoids as therapeutics in retinal disease. Neural Plast 2016. doi:Artn 8373020. https://doi.org/10.1155/2016/8373020, 2016, 1, 12.
Lax P, Esquiva G, Altavilla C, Cuenca N. Neuroprotective effects of the cannabinoid agonist HU210 on retinal degeneration. Exp Eye Res. 2014;120:175–85. https://doi.org/10.1016/j.exer.2014.01.019.
Krylatov AV, Ugdyshekova DS, Bernatskaya NA, Maslov LN, Mekhoulam R, Pertwee RG, et al. Activation of type II cannabinoid receptors improves myocardial tolerance to arrhythmogenic effects of coronary occlusion and reperfusion. B Exp Biol Med+. 2001;131(6):523–5. https://doi.org/10.1023/A:1012381914518.
Schicho R, Bashashati M, Bawa M, McHugh D, Saur D, Hu HM, et al. The atypical cannabinoid O-1602 protects against experimental colitis and inhibits neutrophil recruitment. Inflamm Bowel Dis. 2011;17(8):1651–64. https://doi.org/10.1002/ibd.21538.
Devane WA, Breuer A, Sheskin T, Jarbe TUC, Eisen MS, Mechoulam R. A novel probe for the cannabinoid receptor. J Med Chem. 1992;35(11):2065–9. https://doi.org/10.1021/jm00089a018.
Aguirre-Rueda D, Guerra-Ojeda S, Aldasoro M, Iradi A, Obrador E, Mauricio MD, et al. WIN 55,212-2, agonist of cannabinoid receptors, prevents amyloid beta1-42 effects on astrocytes in primary culture. PLoS One. 2015;10(4):e0122843. https://doi.org/10.1371/journal.pone.0122843.
More SV, Choi DK. Promising cannabinoid-based therapies for Parkinson’s disease: motor symptoms to neuroprotection. Mol Neurodegener 2015;10. doi: ARTN 17. https://doi.org/10.1186/s13024-015-0012-0.
Song ZH, Slowey CA. Involvement of cannabinoid receptors in the intraocular pressure-lowering effects of WIN55212-2. J Pharmacol Exp Ther. 2000;292(1):136–9.
Oltmanns MH, Samudre SS, Castillo IG, Hosseini A, Lichtman AH, Allen RC, et al. Topical WIN55212-2 alleviates intraocular hypertension in rats through a CB1 receptor-mediated mechanism of action. J Ocul Pharmacol Th. 2008;24(1):104–15. https://doi.org/10.1089/jop.2007.0074.
Gonzalez C, Herradon E, Abalo R, Vera G, Perez-Nievas BG, Leza JC, et al. Cannabinoid/agonist WIN 55,212-2 reduces cardiac ischaemia—reperfusion injury in Zucker diabetic fatty rats: role of CB2 receptors and iNOS/eNOS. Diabetes-Metab Res. 2011;27(4):331–40. https://doi.org/10.1002/dmrr.1176.
de Lago E, Moreno-Martet M, Cabranes A, Ramos JA, Fernandez-Ruiz J. Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects. Neuropharmacology. 2012;62(7):2299–308. https://doi.org/10.1016/j.neuropharm.2012.01.030.
Downer EJ, Clifford E, Amu S, Fallon PG, Moynagh PN. The synthetic cannabinoid R(+)WIN55,212-2 augments interferon-beta expression via peroxisome proliferator-activated receptor-alpha. J Biol Chem. 2012;287(30):25440–53. https://doi.org/10.1074/jbc.M112.371757.
Galve-Roperh I, Sanchez C, Cortes ML, del Pulgar TG, Izquierdo M, Guzman M. Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat Med. 2000;6(3):313–9.
Mueller L, Radtke A, Decker J, Koch M, Belge G. The synthetic cannabinoid WIN 55,212-2 elicits death in human cancer cell lines. Anticancer Res. 2017;37(11):6341–5. https://doi.org/10.21873/anticanres.12086.
Hill KP, Palastro MD, Gruber SA, Fitzmaurice GM, Greenfield SF, Lukas SE, et al. Nabilone pharmacotherapy for cannabis dependence: a randomized, controlled pilot study. Am J Addiction. 2017;26(8):795–801. https://doi.org/10.1111/ajad.12622.
Pergolizzi JV, Taylor R, LeQuang JA, Zampogna G, Raffa RB. Concise review of the management of iatrogenic emesis using cannabinoids: emphasis on nabilone for chemotherapy-induced nausea and vomiting. Cancer Chemoth Pharm. 2017;79(3):467–77. https://doi.org/10.1007/s00280-017-3257-1.
Hernandez SL, Sheyner I, Stover KT, Stewart JT. Dronabinol treatment of refractory nausea and vomiting related to peritoneal carcinomatosis. Am J Hosp Palliat Me. 2015;32(1):5–7. https://doi.org/10.1177/1049909113504240.
Albertson TE, Chenoweth JA, Colby DK, Sutter ME. The changing drug culture: medical and recreational marijuana. FP essentials. 2016;441:11–7.
Ranieri R, Laezza C, Bifulco M, Marasco D, Malfitano AM. Endocannabinoid system in neurological disorders. Recent Pat CNS Drug Discov. 2016;10(2):90–112.
Fernandez-Ruiz J, Moro MA, Martinez-Orgado J. Cannabinoids in neurodegenerative disorders and stroke/brain trauma: from preclinical models to clinical applications. Neurotherapeutics. 2015;12(4):793–806. https://doi.org/10.1007/s13311-015-0381-7.
Aso E, Ferrer I. Cannabinoids for treatment of Alzheimer’s disease: moving toward the clinic. Front Pharmacol. 2014;5:37. https://doi.org/10.3389/fphar.2014.00037.
Hinz B, Ramer R. Anti-tumour actions of cannabinoids. Br J Pharmacol. 2018. https://doi.org/10.1111/bph.14426.
Daris B, Tancer Verboten M, Knez Z, Ferk P. Cannabinoids in cancer treatment: therapeutic potential and legislation. Bosnian J Basic Med Sci. 2018. https://doi.org/10.17305/bjbms.2018.3532.
Olea-Herrero N, Vara D, Malagarie-Cazenave S, Diaz-Laviada I. Inhibition of human tumour prostate PC-3 cell growth by cannabinoids R(+)-methanandamide and JWH-015: involvement of CB2. Brit. J Cancer. 2009;101(6):940–50. https://doi.org/10.1038/sj.bjc.6605248.
Kenyon J, Liu W, Dalgleish A. Report of objective clinical responses of cancer patients to pharmaceutical-grade synthetic cannabidiol. Anticancer Res. 2018;38(10):5831–5. https://doi.org/10.21873/anticanres.12924.
Wilkinson JD, Williamson EM. Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis. J Dermatol Sci. 2007;45(2):87–92. https://doi.org/10.1016/j.jdermsci.2006.10.009.
Naveh N, Weissman C, Muchtar S, Benita S, Mechoulam R. A submicron emulsion of HU-211, a synthetic cannabinoid, reduces intraocular pressure in rabbits. Graefes Arch Clin Exp Ophthalmol 2000;238(4):334–338.
Gado F, Digiacomo M, Macchia M, Bertini S, Manera C. Traditional uses of cannabinoids and new perspectives in the treatment of multiple sclerosis. Medicines. 2018;5(3):91.
Kozela E, Haj C, Hanus L, Chourasia M, Shurki A, Juknat A, et al. HU-446 and HU-465, derivatives of the non-psychoactive cannabinoid cannabidiol, decrease the activation of encephalitogenic T cells. Chem Biol Drug Des. 2016;87(1):143–53. https://doi.org/10.1111/cbdd.12637.
Singh A, Saluja S, Kumar A, Agrawal S, Thind M, Nanda S, et al. Cardiovascular complications of marijuana and related substances: a review. Cardiol Ther. 2018;7(1):45–59. https://doi.org/10.1007/s40119-017-0102-x.
Gorbunov AS, Maslov LN, Tsibulnikov SY, Khaliulin IG, Tsepokina AV, Khutornaya MV, et al. CB-receptor agonist HU-210 mimics the postconditioning phenomenon of isolated heart. Bull Exp Biol Med. 2016;162(1):27–9. https://doi.org/10.1007/s10517-016-3536-6.
Wang PF, Jiang LS, Bu J, Huang XJ, Song W, Du YP, et al. Cannabinoid-2 receptor activation protects against infarct and ischemia-reperfusion heart injury. J Cardiovasc Pharmacol. 2012;59(4):301–7. https://doi.org/10.1097/FJC.0b013e3182418997.
Li Q, Guo HC, Maslov LN, Qiao XW, Zhou JJ, Zhang Y. Mitochondrial permeability transition pore plays a role in the cardioprotection of CB2 receptor against ischemia-reperfusion injury. Can J Physiol Pharmacol. 2014;92(3):205–14. https://doi.org/10.1139/cjpp-2013-0293.
Ortega A, Garcia-Hernandez VM, Ruiz-Garcia E, Meneses-Garcia A, Herrera-Gomez A, Aguilar-Ponce JL, et al. Comparing the effects of endogenous and synthetic cannabinoid receptor agonists on survival of gastric cancer cells. Life Sci. 2016;165:56–62. https://doi.org/10.1016/j.lfs.2016.09.010.
Fattore L, Fratta W. Beyond THC: the new generation of cannabinoid designer drugs. Front Behav Neurosci 2011;5. doi:ARTN 60. https://doi.org/10.3389/fnbeh.2011.00060.
Kong TY, Kim JH, Kim DK, Lee HS. Synthetic cannabinoids are substrates and inhibitors of multiple drug-metabolizing enzymes. Arch Pharm Res. 2018;41(7):691–710. https://doi.org/10.1007/s12272-018-1055-x.
Holm NB, Nielsen LM, Linnet K. CYP3A4 mediates oxidative metabolism of the synthetic cannabinoid AKB-48. AAPS J. 2015;17(5):1237–45. https://doi.org/10.1208/s12248-015-9788-7.
Kong TY, Kim JH, Kwon SS, Cheong JC, Kim HS, In MK, et al. Inhibition of cytochrome P450 and uridine 5’-diphospho-glucuronosyltransferases by MAM-2201 in human liver microsomes. Arch Pharm Res. 2017;40(6):727–35. https://doi.org/10.1007/s12272-017-0917-y.
Zendulka O, Dovrtelova G, Noskova K, Turjap M, Sulcova A, Hanus L, et al. Cannabinoids and cytochrome P450 interactions. Curr Drug Metab. 2016;17(3):206–26. https://doi.org/10.2174/1389200217666151210142051.
Tai S, Fantegrossi WE. Pharmacological and Toxicological effects of synthetic cannabinoids and their metabolites. Curr Top Behav Neurosci. 2017;32:249–62. https://doi.org/10.1007/7854_2016_60.
Fantegrossi WE, Wilson CD, Berquist MD. Pro-psychotic effects of synthetic cannabinoids: interactions with central dopamine, serotonin, and glutamate systems. Drug Metab Rev. 2018;50(1):65–73. https://doi.org/10.1080/03602532.2018.1428343.
Kucerova J, Tabiova K, Drago F, Micale V. Therapeutic potential of cannabinoids in schizophrenia. Recent Pat CNS Drug Discov. 2014;9(1):13–25.
Keimpema E, Mackie K, Harkany T. Molecular model of cannabis sensitivity in developing neuronal circuits. Trends Pharmacol Sci. 2011;32(9):551–61. https://doi.org/10.1016/j.tips.2011.05.004.
Keimpema E, Tortoriello G, Alpar A, Capsoni S, Arisi I, Calvigioni D, et al. Nerve growth factor scales endocannabinoid signaling by regulating monoacylglycerol lipase turnover in developing cholinergic neurons. P Natl Acad Sci USA. 2013;110(5):1935–40. https://doi.org/10.1073/pnas.1212563110.
Velasco G, Hernandez-Tiedra S, Davila D, Lorente M. The use of cannabinoids as anticancer agents. Prog Neuro-Psychoph. 2016;64:259–66. https://doi.org/10.1016/j.pnpbp.2015.05.010.
Velasco G, Hernandez-Tiedra S, Davila D, Lorente M. Corrigendum to “The use of cannabinoids as anticancer agents” [Prog. Neuro-Psychopharmacol. Biol. Psychiatry 64 (2016) 259–266]. 2017;74:57. https://doi.org/10.1016/j.pnpbp.2016.12.005.
Volz MS, Siegmund B, Hauser W. Efficacy, tolerability, and safety of cannabinoids in gastroenterology. A systematic review. Schmerz. 2016;30(1):37–46. https://doi.org/10.1007/s00482-015-0087-0.
Singh Y, Bali C. Cannabis extract treatment for terminal acute lymphoblastic leukemia with a Philadelphia chromosome mutation. Case Rep Oncol. 2013;6(3):585–92. https://doi.org/10.1159/000356446.
Ladin DA, Soliman E, Griffin L, Van Dross R. Preclinical and clinical assessment of cannabinoids as anti-cancer agents. Front Pharmacol 2016;7. doi:ARTN 361. https://doi.org/10.3389/fphar.2016.00361.
Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare that they have no conflict of interest.
Additional information
This article is part of the Topical Collection on Chemical and Molecular Toxicology
Rights and permissions
About this article
Cite this article
Muralidhar Reddy, P., Maurya, N. & Velmurugan, B.K. Medicinal Use of Synthetic Cannabinoids—a Mini Review. Curr Pharmacol Rep 5, 1–13 (2019). https://doi.org/10.1007/s40495-018-0165-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40495-018-0165-y